Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: Learnings from the Zoster Quality of Life (ZQOL) study

被引:5
作者
Carroll S. [1 ]
Gater A. [2 ]
Abetz-Webb L. [2 ]
Smith F. [3 ]
Demuth D. [3 ]
Mannan A. [1 ]
机构
[1] Sanofi-Pasteur MSD, Berkshire
[2] Adelphi Values, Cheshire
[3] Adelphi Real World, Cheshire
关键词
Burden; Herpes zoster; Post-herpetic neuralgia; Real-world;
D O I
10.1186/1756-0500-6-486
中图分类号
学科分类号
摘要
Background: Acute presentation of herpes zoster (HZ) and the subsequent development of post-herpetic neuralgia (PHN) can have a significant impact on patients' lives. To date, evidence regarding the human and economic burden of HZ and PHN in the UK is limited. To address this knowledge gap a national, multicentre, large-scale real-world study was conducted to inform the scientific community and healthcare decision-makers. This paper outlines difficulties encountered and challenges to conducting real-world studies in the UK, methods used to overcome these hurdles and strategies that can be employed to promote and facilitate the conduct of future studies. Findings. The Zoster Quality of Life (ZQOL) study is the first UK-wide and largest observational study investigating patient burden associated with HZ and PHN. A total of 383 patients (229 HZ; 154 PHN) over the age of 50 years were recruited from 42 primary and secondary/tertiary care centres. Patient-reported outcome (PRO) assessments of pain, quality of life and treatment satisfaction were completed by all participants and supplemented by clinical information from participating physicians.Key challenges encountered during the conduct of this study can be broadly categorised as follows: 1) identification of centres willing/able to participate in the study: lack of resources and limited research experience were major barriers to recruitment of centres for participation in the study; 2) obtaining local research & development (R&D) approval: lack of clearly defined processes and requirements specific to real-world studies and limited degree of standardisation between R&D departments in approval procedures led to significant variability in submission requirements and lead times for obtaining approval; 3) recruitment of study participants: rates of recruitment were slower than anticipated, meaning it was necessary to extend the study recruitment period and increase the number of participating centres. Discussion. Initiatives designed to promote and facilitate the conduct of research in the UK are important for real-world studies. The ZQOL study shows that opportunities exist for real-word research. However, streamlining the R&D approval process where possible and further incentivising the participation of primary care centres in such studies would help to further facilitate the generation of real-world evidence to inform healthcare decisions. © 2013 Carroll et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
[1]  
Cohen J., Powderly W.G., Berkley S.F., Calandra T., Clumeck N., Finch R.G., Infectious Diseases. 2nd Ed, (2003)
[2]  
Brisson M., Edmunds W.J., Law B., Gay N.J., Walld R., Brownell M., Roos L., De Serres G., Epidemiology of varicella zoster virus infection in Canada and the United Kingdom, Epidemiology and Infection, 127, 2, pp. 305-314, (2001)
[3]  
Edmunds W.J., Brisson M., Rose J.D., The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales, Vaccine, 19, 23-24, pp. 3076-3090, (2001)
[4]  
Schmader K., Gnann J.W., Watson C.P., The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine, J Infect Dis, 197, SUPPL. 2, (2008)
[5]  
Dworkin R.H., Schmader K.E., Herpes zoster and postherpetic neuralgia. 2nd ed, The Epidemiology and Natural History of Herpes Zoster and Postherpetic Neuralgia, pp. 39-64, (2001)
[6]  
Drolet M., Brisson M., Schmader K.E., Levin M.J., Johnson R., Oxman M.N., Patrick D., Blanchette C., Mansi J.A., The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: A prospective study, Can Med Assoc J, 182, 16, pp. 1731-1736, (2010)
[7]  
Schmader K.E., Sloane R., Pieper C., Coplan P.M., Nikas A., Saddier P., Chan I.S.F., Choo P., Levin M.J., Johnson G., Williams H.M., Oxman M.N., The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults, Clinical Journal of Pain, 23, 6, pp. 490-496, (2007)
[8]  
Van Seventer R., Sadosky A., Lucero M., Dukes E., A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia, Age Ageing, 35, 2, pp. 132-137, (2006)
[9]  
Scott F.T., Johnson R.W., Leedham-Green M., Davies E., Edmunds W.J., Breuer J., The burden of Herpes Zoster: A prospective population based study, Vaccine, 24, 9, pp. 1308-1314, (2006)
[10]  
Oster G., Harding G., Dukes E., Edelsberg J., Cleary P.D., Pain, medication Use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey, J Pain, 6, 6, pp. 356-363